CervoMed Inc. (CRVO) stock
Close on Nov 13, 2026Market cap $25.55MP/E –Yield –
CervoMed Inc. saw revenue fall 99.9% to $8.73K over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $25.55M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $25.55M
- P/E ratio
- –
- Price to sales
- 2928.18
- Price to book
- 1.47
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $8.73K
- Net income
- -$28.52M
- EPS, diluted
- -$2.76
- Book value per share
- $1.15
- Diluted shares
- 15M
Trading
- Next earnings
- Mar 16, 2027 (estimated, after the close)
- Previous close
- $1.83
- Open
- $1.75
- Day's range
- $1.64 – $1.79
- Volume
- 640,375
- Average volume (20 days)
- 956,444
- Beta (5 years)
- 0.55
- 52-week range
- $1.27 – $10.00
- RSI (14 days)
- 40.4
- Volatility (1 year)
- 121.5%
- Relative volume
- 1.34×
- WACC
- 7.9%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRVO | S&P 500 | Difference | CRVO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.6% | -3.0% | −22.5 pts | ||
| 3 months | -42.3% | -2.8% | −39.5 pts | ||
| Year to date | -78.6% | +11.5% | −90.1 pts | ||
| 1 year | -76.7% | +13.5% | −90.2 pts | ||
| 3 years | -82.6% | +77.7% | −160.3 pts | -44.2% | +21.1% |
| 5 years | -94.7% | +72.6% | −167.3 pts | -44.5% | +11.5% |
| 10 years | -100.0% | +308.2% | −408.1 pts | -54.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CervoMed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About CervoMed
Pharmaceutical Preparations
CervoMed Inc. is a clinical-stage biotechnology company focused on developing therapies for age-related degenerative brain disorders. The company's lead drug candidate, neflamapimod, is an orally administered small-molecule inhibitor of the p38α enzyme designed to reduce neuroinflammation, reverse synaptic dysfunction, and slow neuron degeneration. Its pipeline addresses diseases of the central nervous system, with its primary clinical focus on dementia with Lewy bodies. It also evaluates neflamapimod in clinical studies for conditions such as non-fluent variant primary progressive aphasia, recovery after stroke, and amyotrophic lateral sclerosis. The company targets patients experiencing synaptic deficits before irreversible neuronal loss occurs.
Company profile, executives and historyCervoMed stock: common questions
What is CervoMed's stock price?
CRVO closed at $1.69 on Nov 13, 2026, down 7.65% on the day. Over the past 52 weeks it traded between $1.27 and $10.00.
What is CervoMed's market cap?
CervoMed was worth $25.55M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is CRVO's P/E ratio?
CervoMed lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.76), so it has no meaningful P/E ratio.
How much revenue does CervoMed make?
CervoMed reported revenue of $8.73K for the twelve months to Sep 30, 2026, down 99.9% from a year earlier.
Does CervoMed pay a dividend?
No. CervoMed has not paid a cash dividend over the last twelve months.
When does CervoMed report earnings next?
CervoMed is expected to report Q4 FY2026 results on Mar 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CRVO stock performed over the past year?
Including dividends, CRVO returned -76.7% over the past year, against +13.5% for the S&P 500.
How many CRVO shares are sold short?
1M shares were sold short at the latest FINRA report, 12.71% of the float, or 4.7 days of average trading volume.
Who are CervoMed's competitors?
Companies most similar to CervoMed by business, industry and size include JUNS, ADXN, GNLX, AZTR, KPRX.
See a number that looks wrong?